Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hisun-Pfizer Split: What Went Wrong And What Next?

Executive Summary

The breakup of the Hisun-Pfizer JV typifies an unhappy marriage between Chinese and MNC pharma firms in the generics segment in recent years, although the two companies will continue to work as commercial partners under a new framework. Scrip delves into the reasons for the split and also outlines why, China is, nevertheless, expected to see more joint ventures for innovative drugs.


Related Content

Deal Watch: Vertex Selects First Candidate Under CRISPR Gene-Editing Collaboration
Fosun Kite Bets On Cell Therapy Despite Approval Pathway Lag In China
Nascent Deal Helps Hisun Advance Innovation Goals
Santen JV To Become China’s ‘Largest Ophthalmic Site’
Hisun Braces For Hit From US FDA Import Alert
Wuxi PharmaTech Pushing Ahead with $3bn Go-Private Deal
China Generic Sildenafil Market Growing But Challenges Ahead
Game Of Thrones: Bayer Looks To Lead China’s OTC Market
Pfizer Looks To Ramp Up Branded Generics Via MOU With China's Hisun


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts